Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Tipifarnib in Patients With High-Risk Myelodysplastic Syndrome (MDS)
This study has been completed.
Study NCT00050154   Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received: November 22, 2002   Last Updated: November 20, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndrome
Additional conditions recognized in this trial
Myelodysplastic Syndromes
Preleukemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Hematologic Diseases
Neoplasms
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
ZARNESTRA, tipifarnib, R115777
Additional drug interventions recognized in this trial
Tipifarnib
More general drug interventions related to this trial
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Johnson &Johnson Pharmaceutical Research &Development, L.L.C.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services